Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers
Clinical trial NCT03868072 · COMPLETED
Trial details
- NCT number
- NCT03868072
- Sponsor
- Chong Kun Dang Pharmaceutical
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-22
- Primary completion
- 2019-03-29
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.